These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 19644832)

  • 1. [The role of steroids in the treatment of IgA nephropathy].
    Coppo R; Pozzi C; Amore A
    G Ital Nefrol; 2009; 26(4):421-41. PubMed ID: 19644832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of therapeutic agents on the inflammatory and fibrogenic factors in IgA nephropathy.
    Ihm CG; Jeong KW; Lee SH; Lee TW; Park JK
    Nephrology (Carlton); 2007 Dec; 12 Suppl 3():S25-6. PubMed ID: 17995524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IgA glomerulonephritis: beyond angiotensin-converting enzyme inhibitors.
    Locatelli F; Vecchio LD; Pozzi C
    Nat Clin Pract Nephrol; 2006 Jan; 2(1):24-31. PubMed ID: 16932386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pediatric IgA nephropathy: clinical and therapeutic perspectives.
    Coppo R
    Semin Nephrol; 2008 Jan; 28(1):18-26. PubMed ID: 18222343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fractional urinary excretion of IgG is the most powerful predictor of renoprotection by ACE inhibitors in IgA nephropathy.
    Bazzi C; Rizza V; Paparella M; Casellato D; Napodano P; Olivieri G; D'Amico G
    J Nephrol; 2009; 22(3):387-96. PubMed ID: 19557716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoamine oxidase inhibitors for IgA nephropathy.
    Altschuler EL
    Med Hypotheses; 2001 Feb; 56(2):225-6. PubMed ID: 11425292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A validated model of disease progression in IgA nephropathy.
    Magistroni R; Furci L; Leonelli M; Masellis M; Ligabue G; Lucchi L; Lupo A; Brezzi B; Gambaro G; Manganelli L; Pedrazzi G; Ricardi M; Bormioli L; Albertazzi A
    J Nephrol; 2006; 19(1):32-40. PubMed ID: 16523423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Considerations on the treatment of IgA nephropathy on the basis of the results of the latest studies (STOP-IgAN, TESTING, NEFIGAN)].
    Nagy J; Sági B; Máté J; Vas T; Kovács T
    Orv Hetil; 2017 Dec; 158(49):1946-1952. PubMed ID: 29199436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune modulating therapy for IgA nephropathy: rationale and evidence.
    Floege J; Eitner F
    Semin Nephrol; 2008 Jan; 28(1):38-47. PubMed ID: 18222345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of poor outcomes in steroid therapy for immunoglobulin A nephropathy.
    Shimizu A; Takei T; Uchida K; Tsuchiya K; Nitta K
    Nephrology (Carlton); 2009 Aug; 14(5):521-6. PubMed ID: 19674320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of tonsillectomy in pediatric IgA nephropathy.
    Mariotti AJ; Agrawal R; Hotaling AJ
    Arch Otolaryngol Head Neck Surg; 2009 Jan; 135(1):85-7. PubMed ID: 19153312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural history of primary IgA nephropathy.
    Berthoux FC; Mohey H; Afiani A
    Semin Nephrol; 2008 Jan; 28(1):4-9. PubMed ID: 18222341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of first renal biopsy histology for therapeutic selection in IgA nephropathy.
    Shigematsu H; Koyama A
    Nihon Jinzo Gakkai Shi; 1994 Apr; 36(4):331-8. PubMed ID: 8022105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can immunosuppressive therapy be useful in IgA nephropathy when the 'Point of No Return' has already been exceeded?
    Pozzi C; Del Vecchio L; Locatelli F
    Nephron; 2002; 92(3):699-701. PubMed ID: 12372958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Present and future therapy options in IgA-nephropathy.
    Floege J; Eitner F
    J Nephrol; 2005; 18(4):354-61. PubMed ID: 16245237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgA nephropathy and psoriatic arthritis that improved with steroid pulse therapy and mizoribine in combination with treatment for chronic tonsillitis and epipharyngitis.
    Kaneko T; Mii A; Fukui M; Nagahama K; Shimizu A; Tsuruoka S
    Intern Med; 2015; 54(9):1085-90. PubMed ID: 25948353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concise semiquantitative histological scoring system for immunoglobulin A nephropathy.
    Jiang L; Liu G; Lv J; Huang C; Chen B; Wang S; Zou W; Zhang H; Wang H
    Nephrology (Carlton); 2009 Sep; 14(6):597-605. PubMed ID: 19422527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Idiopathic IgA nephropathy: pathogenesis, histopathology, and therapeutic options.
    Tumlin JA; Madaio MP; Hennigar R
    Clin J Am Soc Nephrol; 2007 Sep; 2(5):1054-61. PubMed ID: 17702711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunosuppressive and non-immunosuppressive agents for patients with IgA nephropathy: guideline from the Italian Society of Nephrology].
    Pozzi C; Manno C; Passerini P; Strippoli GF; Lupo A; Stratta P; Cagnoli L;
    G Ital Nefrol; 2007; 24 Suppl 37():S30-49. PubMed ID: 17347954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of IgA nephropathy].
    Matousovic K; Mestecky J; Tomana M; Novak J
    Vnitr Lek; 2008 Mar; 54(3):239-44. PubMed ID: 18522291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.